Cargando…
Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration
Since therapeutic peptides and oligonucleotides are gathering interests as active pharmaceutical ingredients (APIs), nanoparticulate drug delivery systems are becoming of great importance. Thereby, the possibility to design drug delivery systems according to the therapeutic needs of APIs enhances cl...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102448/ https://www.ncbi.nlm.nih.gov/pubmed/27828968 http://dx.doi.org/10.1371/journal.pone.0164149 |
_version_ | 1782466430924488704 |
---|---|
author | Scheicher, Bernhard Lorenzer, Cornelia Gegenbauer, Katrin Partlic, Julia Andreae, Fritz Kirsch, Alexander H. Rosenkranz, Alexander R. Werzer, Oliver Zimmer, Andreas |
author_facet | Scheicher, Bernhard Lorenzer, Cornelia Gegenbauer, Katrin Partlic, Julia Andreae, Fritz Kirsch, Alexander H. Rosenkranz, Alexander R. Werzer, Oliver Zimmer, Andreas |
author_sort | Scheicher, Bernhard |
collection | PubMed |
description | Since therapeutic peptides and oligonucleotides are gathering interests as active pharmaceutical ingredients (APIs), nanoparticulate drug delivery systems are becoming of great importance. Thereby, the possibility to design drug delivery systems according to the therapeutic needs of APIs enhances clinical implementation. Over the last years, the focus of our group was laid on protamine-oligonucleotide-nanoparticles (so called proticles), however, the possibility to modify the size, zeta potential or loading efficiencies was limited. Therefore, at the present study we integrated a stepwise addition of protamine (titration) into the formation process of proticles loaded with the angiogenic neuropeptide secretoneurin (SN). A particle size around 130 nm was determined when proticles were assembled by the commonly used protamine addition at once. Through application of the protamine titration process it was possible to modify and adjust the particle size between approx. 120 and 1200 nm (dependent on mass ratio) without influencing the SN loading capacity. Dynamic light scattering pointed out that the difference in particle size was most probably the result of a secondary aggregation. Initially-formed particles of early stages in the titration process aggregated towards bigger assemblies. Atomic-force-microscopy images also revealed differences in morphology along with different particle size. In contrast, the SN loading was only influenced by the applied mass ratio, where a slight saturation effect was observable. Up to 65% of deployed SN could be imbedded into the proticle matrix. An in-vivo biodistribution study (i.m.) showed a retarded distribution of SN from the site of injection after the application of a SN-proticle formulation. Further, it was demonstrated that SN loaded proticles can be successfully freeze-dried and resuspended afterwards. To conclude, the integration of the protamine titration process offers new possibilities for the formulation of proticles in order to address key parameters of drug delivery systems as size, API loading or modified drug release. |
format | Online Article Text |
id | pubmed-5102448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-51024482016-11-18 Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration Scheicher, Bernhard Lorenzer, Cornelia Gegenbauer, Katrin Partlic, Julia Andreae, Fritz Kirsch, Alexander H. Rosenkranz, Alexander R. Werzer, Oliver Zimmer, Andreas PLoS One Research Article Since therapeutic peptides and oligonucleotides are gathering interests as active pharmaceutical ingredients (APIs), nanoparticulate drug delivery systems are becoming of great importance. Thereby, the possibility to design drug delivery systems according to the therapeutic needs of APIs enhances clinical implementation. Over the last years, the focus of our group was laid on protamine-oligonucleotide-nanoparticles (so called proticles), however, the possibility to modify the size, zeta potential or loading efficiencies was limited. Therefore, at the present study we integrated a stepwise addition of protamine (titration) into the formation process of proticles loaded with the angiogenic neuropeptide secretoneurin (SN). A particle size around 130 nm was determined when proticles were assembled by the commonly used protamine addition at once. Through application of the protamine titration process it was possible to modify and adjust the particle size between approx. 120 and 1200 nm (dependent on mass ratio) without influencing the SN loading capacity. Dynamic light scattering pointed out that the difference in particle size was most probably the result of a secondary aggregation. Initially-formed particles of early stages in the titration process aggregated towards bigger assemblies. Atomic-force-microscopy images also revealed differences in morphology along with different particle size. In contrast, the SN loading was only influenced by the applied mass ratio, where a slight saturation effect was observable. Up to 65% of deployed SN could be imbedded into the proticle matrix. An in-vivo biodistribution study (i.m.) showed a retarded distribution of SN from the site of injection after the application of a SN-proticle formulation. Further, it was demonstrated that SN loaded proticles can be successfully freeze-dried and resuspended afterwards. To conclude, the integration of the protamine titration process offers new possibilities for the formulation of proticles in order to address key parameters of drug delivery systems as size, API loading or modified drug release. Public Library of Science 2016-11-09 /pmc/articles/PMC5102448/ /pubmed/27828968 http://dx.doi.org/10.1371/journal.pone.0164149 Text en © 2016 Scheicher et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Scheicher, Bernhard Lorenzer, Cornelia Gegenbauer, Katrin Partlic, Julia Andreae, Fritz Kirsch, Alexander H. Rosenkranz, Alexander R. Werzer, Oliver Zimmer, Andreas Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration |
title | Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration |
title_full | Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration |
title_fullStr | Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration |
title_full_unstemmed | Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration |
title_short | Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration |
title_sort | manufacturing of a secretoneurin drug delivery system with self-assembled protamine nanoparticles by titration |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102448/ https://www.ncbi.nlm.nih.gov/pubmed/27828968 http://dx.doi.org/10.1371/journal.pone.0164149 |
work_keys_str_mv | AT scheicherbernhard manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration AT lorenzercornelia manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration AT gegenbauerkatrin manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration AT partlicjulia manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration AT andreaefritz manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration AT kirschalexanderh manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration AT rosenkranzalexanderr manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration AT werzeroliver manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration AT zimmerandreas manufacturingofasecretoneurindrugdeliverysystemwithselfassembledprotaminenanoparticlesbytitration |